Balchem Corporation announced that it completed its acquisition of Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. The signing of a definitive agreement to acquire Kappa Bioscience AS was previously announced on June 14, 2022.
Related Posts
Balchem Announces Dividend
Ted Harris, Balchem’s Chairman, President and CEO, said, “Balchem has a long-standing commitment to an annual dividend and we are pleased to announce the continuation of that commitment."
Balchem Corporation Reports Third Quarter 2024 Financial Results
Ted Harris, Chairman, President and CEO said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth."
